Medicinal cannabis reference group will gather stakeholders
In November 2021, a majority of the Danish Parliament voted in favour of continuing the medicinal cannabis pilot programme from 2022.
The act turned the pilot programme’s possibility to cultivate and manufacture cannabis products into a permanent solution, while at the same time extending the pilot programme’s opportunity for doctors to prescribe cannabis products until the end of 2025.
Under the act, the Danish Medicines Agency will also form a medicinal cannabis reference group with the purpose of establishing a forum in which authorities, industry, medical experts and patient representatives can discuss the pilot programme and any challenges related thereto.
The reference group will generally hold one meeting a year. The composition of the group appears from the established terms of reference (see below).
Read the terms of reference of the reference group (hyperlink)